Phase I clinical trial of weekly iv 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY).

Abstract

In a phase I trial, 2,3-dihydro-1H-imidazo[1,2-b]pyrazole was administered iv weekly at doses ranging from 0.1 to 3.0 g/m2/wk to patients with refractory metastatic solid tumors. Although gastrointestinal toxicity was tolerable and neither granulocyte nor platelet toxicity was seen, significant dose-limiting hemolysis was encountered at doses of 1.5 g/m2/wk. While no definite tumor regressions were seen in the 32 patients evaluable for response, two patients (squamous cell carcinoma of lung and tonsil) had clinically useful improvement.

• Authors: C L Vogel, J M Denefrio, D C Padgett, M A Silverman
• Journal: Cancer treatment reports (Cancer Treat Rep) 1980 Oct-Nov Vol. 64 Issue 10-11 Pg. 1153-6 ISSN: 0361-5960 [Print] United States
• PMID: 7459903 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Imidazoles
• Pyrazoles
• 2,3-dihydro-1H-imidazo(1,2-b)pyrazole

Topics

• Antineoplastic Agents (adverse effects, therapeutic use)
• Drug Evaluation
• Female
• Humans
• Imidazoles (adverse effects, therapeutic use)
• Male
• Middle Aged
• Neoplasms (drug therapy)
• Pyrazoles (adverse effects, therapeutic use)